Evidence map›Paper›PMID 29572372›Full record

ArticleBMJ case reports2018

Parkinson's disease with hypocalcaemia: adult presentation of 22q11.2 deletion syndrome.

Fradique Moreira, Ana Brás, Joana Ramos Lopes, Cristina Januário

Abstract readCase Reports
In one paragraph

Article in BMJ case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. 22q11.2 Deletion Syndrome-Associated Parkinson's Disease.Movement disorders clinical practice · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Fradique MoreiraDivision of Movement Disorders, Department of Neurology, Coimbra Hospital and University Centre, Coimbra, Portugal.ORCID http://orcid.org/0000-0002-5881-4950
Ana BrásDepartment of Neurology, Coimbra Hospital and University Centre, Coimbra, Portugal.
Joana Ramos LopesDepartment of Neurology, Coimbra Hospital and University Centre, Coimbra, Portugal.
Cristina JanuárioDivision of Movement Disorders, Department of Neurology, Coimbra Hospital and University Centre, Coimbra, Portugal.
University of Coimbra · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A growing amount of evidence indicates that 22q11.2 deletion syndrome (22q11.2DS) increases the risk of early-onset Parkinson's disease (EOPD). Here, we describe a 36-year-old patient with EOPD. The patient presented with 22q11.2DS features, including associated cognitive disabilities, hypocalcaemia and facial dysmorphia that led us to screen for and confirm this deletion. In addition, hypocalcaemia and vitamin D deficiency were the main factors responsible for severe, painful muscle spasms that were non-levodopa (L-Dopa) responsive and remitted after calcium and vitamin D replacement therapy. Many patients with this deletion remain undiagnosed until adulthood due to the absence of 'major' phenotypic hallmarks, which usually present during early childhood. Later onset problems involving various medical subspecialties are increasingly recognised as important components of 22q11.2DS. Therefore, the multisystem nature and associated burden of morbidities demand a high degree of suspicion for this entity from all clinicians regardless of their medical subspecialty.

Indexed as

AdultCalcitriolCalcium CarbonateDiagnosis, DifferentialDiGeorge SyndromeHumansHypocalcemiaMaleParkinson DiseaseTomography, Emission-Computed, Single-PhotonCalcitriolCalcium Carbonatecalcium and bonegeneticsneurologyparkinson’s disease

Identifiers

PMID29572372
PMCPMC5878318
OpenAlexW2790309821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.